Pathway to ABSSSI Efficacy
Broad Coverage for ABSSSI: gram-positive pathogens, including MRSA, and gram-negative pathogens, including Pseudomonas aeruginosa. See full Indication
See Baxdela ABSSSI Efficacy ResultsExplore ABSSSI Safety & Tolerability
See Baxdela ABSSSI Safety ProfileDosing & Administration
See BAXDELA Dosing & Administration
Melinta Therapeutics, LLC - The Antibiotics Company
Medical Information
For medical inquiries or to report an adverse event, other safety-related information, or product complaints for a company product, please contact Medical Information.
Phone: 1-844-MED-MLNT (1-844-633-6568)
medinfo@melinta.com
www.melintamedicalinformation.com
©2021 All rights reserved. PP-BAX-US-0399 Terms of Use
BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.